查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1419139

骨坏死治疗市场规模和预测、全球和地区份额、趋势和成长机会分析报告范围：按治疗类型、最终用户和地理位置

Osteonecrosis Treatment Market Size and Forecasts, Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Treatment Type, End User, and Geography
出版日期: | 出版商: The Insight Partners | 英文 150 Pages | 商品交期: 1-5个工作天内

价格
简介目录

骨坏死治疗市场规模预计将从2022年的6.37亿美元成长到2030年的10.21亿美元；预计2022年至2030年市场CAGR为6.08%。

推动市场成长的关键因素包括由于交通事故数量增加以及患者长期使用类固醇导致的骨坏死病例增加。此外，老年人口的增加和骨骼健康意识的增强也有利于骨坏死治疗市场。然而，与手术治疗相关的高成本以及与治疗药物相关的风险因素阻碍了骨坏死治疗市场。

骨坏死，也称为股骨头缺血性坏死 (AVN)，是一种导致骨细胞死亡的疼痛性骨病变。当流向骨骼的血液受到干扰并随着时间的推移而恶化时，就会发生这种情况。造成这种情况的原因包括骨折、髋关节脱臼、放射线治疗和酗酒。

骨科损伤病例的增加和老年人口的增加推动骨坏死治疗市场的成长

根据 Clevelandclinic.org 2021 年发布的统计数据，每年有 10,000-20,000 名美国人被诊断出患有缺血性坏死 (AVN)，该疾病影响所有年龄和性别的个人。近 20% 经历髋关节脱位的人会出现 AVN。由于致命事故造成的骨骼和关节损伤数量不断增加，全球骨坏死病例不断增加。虽然股骨头坏死更常见于髋部，但它也会影响肱骨、膝盖和距骨的健康状况。根据 StatPearls 2023 年发表的一篇文章，美国 10% 的髋关节置换术是由 AVN 造成的，其中大多数是 30-65 岁的人。髋部或膝盖移位可能会切断腿部的血液供应。结果，腿部组织可能无法获得足够的血液（一种称为缺血的情况）并且可能死亡（一种称为坏死的情况）。肘部或上臂骨折有时会阻碍前臂的血液流动，产生类似的併发症。当骨骼的血液供应中断时，一部分骨骼可能会死亡，导致骨坏死。根据 PubMed Central 2022 年 1 月发表的文章，一项队列研究纳入了 170,934 名严重创伤患者。研究结论，78.0%的外伤性髋关节脱位的重大创伤患者是在道路交通事故中受伤的，特别是机动车事故（49.9%）。

老年人更容易出现骨坏死，因为他们更容易发生骨质退化和骨折。 PubMed 于 2020 年发表的一篇文章中进行了一项研究，旨在评估空心内固定对 73 名股骨颈骨折 (FNF) 患者的长期结局的有效性，同时确定影响结局的危险因素。研究结果显示，7人（即~10%）经历了股骨头坏死，4人接受了髋关节置换手术。根据世界卫生组织(WHO) 统计，到2030 年，全球每6 人中就有1 人年龄在60 岁或以上，预计60 岁以上人口将达到14 亿。因此，不断增长的老年人口和日益增强的骨骼健康意识有利骨坏死治疗市场。

市场机会

生物力学解决方案的开发和正在进行的临床试验以推出新的创新正在创造市场机会。

用于股骨头坏死治疗的生物力学技术试图解决关节力学和功能问题。 AVN 经常会引起骨骼结构变化，尤其是负重关节，导致不适和活动能力下降。生物力学解决方案对于保护关节功能、减轻疼痛和改善患者的生活品质至关重要。这些方法通常涉及骨科医生、生物力学工程师和復健专家之间的多学科合作，以提供全面的护理。目前正在研究和利用各种生物力学方法来治疗 AVN。这些方法包括开发专门的、可客製化的植入物，用于针对患者的特定治疗，以及使用先进的成像技术进行生物力学分析，以了解改变的患者生物力学。例如，在Sage Journals 于2023 年1 月发表的一篇文章中，开展了一项研究，透过恢復9 名接受血管化骨移植和临时桡腕跨内固定治疗的患者的月骨血管供应来阻止股骨头缺血性坏死的进展。研究得出的结论是，利用局部血管化骨移植和临时桡腕内跨越固定提供了一种具有内部固定优点的治疗选择。

同样，Scielo Brazil 在 2023 年 6 月发表的一篇文章中，进行了一项横断面研究，纳入了 9 名被诊断患有股骨头坏死的患者。该研究使用 Vicon 运动捕捉系统进行患者步态分析。研究发现，股骨头坏死的个体会采取代偿步态机制来保护髋关节。这些机制包括骨盆运动增加和膝关节屈曲减少。研究也发现髋部屈曲和内收时刻减少，这可能与这些族群的肌肉无力有关。因此，生物力学分析对于评估 AVN 患者的功能很有用。这使得医生能够评估可显着影响患者生活品质的日常活动。此外，它还帮助他们投资于可以改善疼痛和功能的即时非手术措施，最终带来更好的手术结果。

此外，根据欧盟临床试验登记册，7,255项临床试验是针对18岁以下的受试者进行的，以及年龄较大的儿科试验的资料。根据2023 年3 月发表在MDPI 上的一篇文章，进行了一项开放标籤、非随机、前瞻性临床试验，以评估间质干细胞（MSC）治疗特发性股骨头坏死（ONFH）患者的疗效. ARCO 分类中的阶段低于 IIC。八名患者参与了试验。治疗前 4 週取得自体骨髓 (40 mL)，并依据良好生产规范 (GMP) 标准扩增 MSC。研究得出的结论是，使用自体间质干细胞（MSC）对于股骨头坏死（ONFH）患者来说是一种安全且可能有效的治疗选择。

分部概览

「全球骨坏死治疗市场」根据治疗类型、最终用户和地理位置进行细分。根据产品类型，市场分为药物和手术。药物细分进一步细分为非类固醇抗发炎药、血液稀释剂、降胆固醇药物等。同样，手术细分市场细分为全关节置换/全髋关节置换术（THA）、核心减压手术、骨移植、截骨术等。药品细分市场在2022 年占据最大的市场份额。然而，预计手术细分市场复合CAGR最高可达 7.6%。

就最终用户而言，骨坏死市场分为医院、专科诊所、门诊手术中心等。预计2022年至2030年，医院细分市场将创下市场最高CAGR。骨坏死治疗涉及复杂的手术，需要特殊的医疗关注，包括诊断、治疗和持续监测。医院在为骨坏死患者提供完整的医疗服务方面发挥着至关重要的作用。根据疾病的阶段和严重程度，他们为骨坏死提供各种治疗选择。这些治疗可能包括疼痛管理、物理治疗和生活方式改变等保守技术。此外，严重的情况下可能会进行手术治疗，例如保留关节手术或关节置换手术。

目录

第 1 章：简介

  • 研究范围
  • 市场定义、假设与限制
  • 市场区隔

第 2 章：执行摘要

  • 重要见解
  • 市场吸引力分析

第 3 章：研究方法

第 4 章：骨坏死治疗市场格局

  • 概述
  • PEST分析
  • 生态系分析
    • 价值链供应商名单

第 5 章：骨坏死治疗市场 - 主要市场动态

  • 主要市场驱动因素
  • 主要市场限制
  • 主要市场机会
  • 未来的趋势
  • 驱动因素和限制因素的影响分析

第 6 章：骨坏死治疗市场 - 全球市场分析

  • 骨坏死治疗 - 全球市场概览
  • 骨坏死治疗 - 全球市场与 2030 年预测

第 7 章：骨坏死治疗市场 - 收入分析 - 按治疗类型，2020-2030 年

  • 概述
  • 药品
  • 手术

第 8 章：骨坏死治疗市场 - 收入分析 - 按最终用户，2020-2030 年

  • 概述
  • 医院
  • 专科诊所
  • 门诊手术中心
  • 其他的

第 9 章：骨坏死治疗市场 - 收入分析，2020-2030 - 地理分析

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥

註 - 将为以下提到的地区/国家提供类似的分析

  • 欧洲
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 英国
    • 欧洲其他地区
  • 亚太
    • 澳洲
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋
    • 中东和非洲其他地区
  • 南美洲和中美洲
    • 巴西
    • 阿根廷
    • 南美洲和中美洲其他地区

第 11 章：产业格局

  • 併购
  • 协议、合作、合资企业
  • 新产品发布
  • 扩张和其他策略发展

第 12 章：竞争格局

  • 关键参与者的热图分析
  • 公司定位与专注

第 13 章：骨坏死治疗市场 - 主要公司概况

  • Novartis AG

注意 - 将为以下公司列表提供类似信息

  • 梯瓦製药工业股份有限公司
  • 齐默比美特
  • 辉瑞公司
  • 史赛克
  • 埃克泰克公司
  • 默克公司
  • 雷迪博士实验室有限公司
  • 维亚特里斯公司
  • 地平线治疗公司

第 14 章：附录

  • 词彙表
  • 关于 Insight Partners
  • 市场情报云
简介目录
Product Code: TIPRE00033413

The osteonecrosis treatment market size is expected to grow from US$ 637 million in 2022 to US$ 1,021 million by 2030; the market is estimated to register a CAGR of 6.08% from 2022 to 2030.

Key factors driving the market growth include the rising cases of osteonecrosis in people owing to an increasing number of road accidents and long-term use of steroids among patients. Additionally, the rising geriatric population and growing awareness about bone health benefit the osteonecrosis treatment market. However, the high cost associated with surgical treatments and the risk factors associated with treatment drugs hamper the osteonecrosis treatment market.

Osteonecrosis, also known as avascular necrosis (AVN), is a painful bone disease that results in the death of bone cells. It happens when blood flow to bones is disrupted and worsens over time. The causes of this condition include broken bones, dislocated hips, radiation therapy, and alcohol abuse.

Rising Cases of Orthopedic Injuries and Increasing Geriatric Population Drive Osteonecrosis Treatment Market Growth

According to statistics published by Clevelandclinic.org in 2021, 10,000-20,000 Americans are diagnosed with avascular necrosis (AVN) annually, with the condition affecting individuals of all ages and genders. Nearly 20% of people who experience hip dislocation develop AVN. The cases of osteonecrosis are rising globally owing to the increasing number of bone and joint injuries caused by fatal accidents. Although osteonecrosis more commonly affects the hip, it can also hamper the condition of the humerus, knee, and talus. As per an article published by StatPearls in 2023, AVN causes 10% of hip arthroplasties in the US, mostly in people aged 30-65. A displaced hip or knee might cut off blood supply to the leg. As a result, the tissues in the leg may not receive enough blood (a condition known as ischemia) and may die (a condition known as necrosis). Elbow or upper arm fractures can occasionally impede blood flow to the forearm, creating similar complications. When blood supply to a bone is interrupted, a portion of the bone may die, causing osteonecrosis. As per the article published by PubMed Central in January 2022, a cohort study included 170,934 major trauma patients. The study concluded that 78.0% of the major trauma patients with traumatic hip dislocations were injured in road traffic accidents, particularly in motor vehicle accidents (49.9%).

Older people are more likely to experience osteonecrosis as they are more prone to bone degeneration and fractures. In an article published by PubMed in 2020, a study was carried out to assess the effectiveness of cannulated internal fixation in long-term outcomes in 73 patients with femoral neck fracture (FNF), alongside identifying the risk factors affecting outcomes. The study results showed that 7 (i.e., ~10%) experienced femoral head necrosis, and 4 underwent hip replacement. According to the World Health Organization (WHO), 1 in 6 people worldwide will be aged 60 years or over by 2030, with an estimated 1.4 billion people over 60. Therefore, the burgeoning geriatric population and growing awareness about bone health favor the osteonecrosis treatment market.

Market Opportunity

Development of Biomechanical Solutions and Ongoing Clinical Trials to Launch New Innovations Are Creating Opportunities in the Market.

Biomechanical techniques for avascular necrosis therapy attempt to solve joint mechanics and functioning concerns. AVN frequently causes structural changes in bone, particularly in weight-bearing joints, resulting in discomfort and decreased mobility. Biomechanical solutions are vital in preserving joint function, reducing pain, and improving a patient's quality of life. These approaches often involve a multidisciplinary collaboration between orthopedic surgeons, biomechanical engineers, and rehabilitation specialists to provide comprehensive care. Various biomechanical approaches are currently being studied and utilized as a treatment for AVN. These approaches include developing specialized and customizable implants for patient-specific treatments and biomechanical analysis using advanced imaging to understand altered patient biomechanics. For instance, in an article published by Sage Journals in January 2023, a study was carried out to stop the advancement of avascular necrosis by restoring lunate vascularity in nine patients who were treated with vascularized bone grafts and interim radiocarpal spanning internal fixation. The study concluded that utilizing a local vascularized bone graft with temporary internal radiocarpal spanning fixation provides a therapeutic option with the advantages of internal immobilization.

Similarly, in an article published by Scielo Brazil in June 2023, a cross-sectional study included nine patients diagnosed with osteonecrosis of the femoral head. The study used Vicon Motion Capture Systems for patients' gait analysis. The study found that individuals with osteonecrosis of the femoral head adopt compensatory gait mechanisms to protect their hip joints. These mechanisms include increased pelvic motion and decreased knee flexion. The study also identified decreased moments for hip flexion and adduction, which may be related to muscle weakness in these groups. Therefore, biomechanical analysis is useful for evaluating the functionality of patients with AVN. This allows physicians to assess daily activities that can significantly affect patients' quality of life. Additionally, it helps them invest in immediate non-operative measures that can improve pain and functionality, eventually leading to better surgical outcomes.

Moreover, according to the European Union Clinical Trials Register, 7255 clinical trials were conducted with subjects under 18 years old, and data on older pediatric trials. According to an article published on MDPI in March 2023, an open-label, non-randomized, prospective clinical trial was conducted to evaluate the efficacy of mesenchymal stem cells (MSCs) in treating idiopathic osteonecrosis of the femoral head (ONFH) in patients with stage less than IIC in the ARCO classification. Eight patients were included in the trial. Autologous bone marrow (40 mL) was obtained four weeks before therapy, and MSCs were expanded under Good Manufacturing Practice (GMP) standards. The study concluded that using autologous mesenchymal stem cells (MSCs) is a safe and potentially effective treatment option for patients with femoral head osteonecrosis (ONFH).

SEGMENTAL OVERVIEW

The "Global Osteonecrosis Treatment Market" is segmented based on treatment type, end user, and geography. Based on product type, the market is bifurcated into drugs and surgeries. Drug segments are further segmented into NSAIDs, blood thinners, cholesterol-lowering drugs, and others. Similarly, the surgeries segment is sub-segmented into total joint replacement/ total hip arthroplasty (THA), core decompression surgery, bone graft, osteotomy, etc. The drugs segment held the largest market share in 2022. However, the surgeries segment is anticipated to grow with the highest CAGR of 7.6%.

In terms of end users, the osteonecrosis market is segmented into hospitals, specialty clinics, ambulatory surgical centers, and others. The hospital segment is expected to record the highest CAGR in the market from 2022 to 2030. Osteonecrosis treatment involves complicated surgeries that need special medical attention, including diagnosis, treatment, and continuous monitoring. Hospitals play an essential role in delivering complete healthcare services to osteonecrosis patients. Depending on the disease's stage and severity, they provide various treatment options for osteonecrosis. Conservative techniques such as pain management, physical therapy, and lifestyle changes may be included in these treatments. Furthermore, surgical therapies such as joint-preserving operations or joint replacement surgeries may be undertaken in severe cases.

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 Market Definition, Assumptions and Limitations
  • 1.3 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights
  • 2.2 Market Attractiveness Analysis

3. Research Methodology

4. Osteonecrosis Treatment Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
  • 4.3 Ecosystem Analysis
    • 4.3.1 List of Vendors in the Value Chain

5. Osteonecrosis Treatment Market - Key Market Dynamics

  • 5.1 Key Market Drivers
  • 5.2 Key Market Restraints
  • 5.3 Key Market Opportunities
  • 5.4 Future Trends
  • 5.5 Impact Analysis of Drivers and Restraints

6. Osteonecrosis Treatment Market - Global Market Analysis

  • 6.1 Osteonecrosis Treatment - Global Market Overview
  • 6.2 Osteonecrosis Treatment - Global Market and Forecast to 2030

7. Osteonecrosis Treatment Market - Revenue Analysis (USD Million) - By Treatment Type, 2020-2030

  • 7.1 Overview
  • 7.2 Drugs
    • 7.2.1 Nonsteroidal Anti-Inflammatory Drugs
    • 7.2.2 Blood Thinners
    • 7.2.3 Cholesterol-Lowering Drugs
    • 7.2.4 Others
  • 7.3 Surgery
    • 7.3.1 Core Decompression Surgery
    • 7.3.2 Osteotomy
    • 7.3.3 Bone Graft
    • 7.3.4 Total joint replacement
    • 7.3.5 Others

8. Osteonecrosis Treatment Market - Revenue Analysis (USD Million) - By End User, 2020-2030

  • 8.1 Overview
  • 8.2 Hospitals
  • 8.3 Specialty Clinics
  • 8.4 Ambulatory Surgical Centers
  • 8.5 Others

9. Osteonecrosis Treatment Market -Revenue Analysis (USD Million), 2020-2030 - Geographical Analysis

  • 9.1 North America
    • 9.1.1 North America Osteonecrosis Treatment Market Overview
    • 9.1.2 North America Osteonecrosis Treatment Market Revenue and Forecasts to 2030
    • 9.1.3 North America Osteonecrosis Treatment Market Revenue and Forecasts and Analysis - By Treatment Type
    • 9.1.4 North America Osteonecrosis Treatment Market Revenue and Forecasts and Analysis - By End User
    • 9.1.5 North America Osteonecrosis Treatment Market Revenue and Forecasts and Analysis - By Countries
      • 9.1.5.1 United States Osteonecrosis Treatment Market
        • 9.1.5.1.1 United States Osteonecrosis Treatment Market, by Treatment Type
        • 9.1.5.1.2 United States Osteonecrosis Treatment Market, by End User
      • 9.1.5.2 Canada Osteonecrosis Treatment Market
        • 9.1.5.2.1 Canada Osteonecrosis Treatment Market, by Treatment Type
        • 9.1.5.2.2 Canada Osteonecrosis Treatment Market, by End User
      • 9.1.5.3 Mexico Osteonecrosis Treatment Market
        • 9.1.5.3.1 Mexico Osteonecrosis Treatment Market, by Treatment Type
        • 9.1.5.3.2 Mexico Osteonecrosis Treatment Market, by End User

Note - Similar analysis would be provided for below mentioned regions/countries

  • 9.2 Europe
    • 9.2.1 Germany
    • 9.2.2 France
    • 9.2.3 Italy
    • 9.2.4 Spain
    • 9.2.5 United Kingdom
    • 9.2.6 Rest of Europe
  • 9.3 Asia-Pacific
    • 9.3.1 Australia
    • 9.3.2 China
    • 9.3.3 India
    • 9.3.4 Japan
    • 9.3.5 South Korea
    • 9.3.6 Rest of Asia-Pacific
  • 9.4 Middle East and Africa
    • 9.4.1 South Africa
    • 9.4.2 Saudi Arabia
    • 9.4.3 U.A.E
    • 9.4.4 Rest of Middle East and Africa
  • 9.5 South and Central America
    • 9.5.1 Brazil
    • 9.5.2 Argentina
    • 9.5.3 Rest of South and Central America

11. Industry Landscape

  • 11.1 Mergers and Acquisitions
  • 11.2 Agreements, Collaborations, Joint Ventures
  • 11.3 New Product Launches
  • 11.4 Expansions and Other Strategic Developments

12. Competitive Landscape

  • 12.1 Heat Map Analysis by Key Players
  • 12.2 Company Positioning and Concentration

13. Osteonecrosis Treatment Market - Key Company Profiles

  • 13.1 Novartis AG
    • 13.1.1 Key Facts
    • 13.1.2 Business Description
    • 13.1.3 Products and Services
    • 13.1.4 Financial Overview
    • 13.1.5 SWOT Analysis
    • 13.1.6 Key Developments

Note - Similar information would be provided for below list of companies

  • 13.2 Teva Pharmaceutical Industries Ltd.
  • 13.3 Zimmer Biomet
  • 13.4 Pfizer Inc
  • 13.5 Stryker
  • 13.6 Exactech Inc
  • 13.7 Merck Co Inc
  • 13.8 Dr Reddy's Laboratories Ltd.
  • 13.9 Viatris Inc
  • 13.10 Horizon Therapeutics plc

14. Appendix

  • 14.1 Glossary
  • 14.2 About The Insight Partners
  • 14.3 Market Intelligence Cloud